Ponsegromab for weight loss in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new medicine called ponsegromab to see if it can help stop weight loss in people with advanced lung cancer. It is given alongside your usual immunotherapy and may help you maintain your strength and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that cannot be removed with surgery.
- You have recently finished chemotherapy combined with radiation, and the cancer has not grown.
- You are scheduled to start a maintenance immunotherapy drug called durvalumab (Imfinzi).
- You have lost more than 5% of your body weight without trying in the past 6 months, or your BMI is under 20 and you've lost more than 2% in that time.
- You do not have certain treatable gene changes (like EGFR or ALK) in the tumor.
- You do not have heart failure, serious liver or kidney problems, or other major medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests whether a nutritional drink with L-carnitine can help people with lung cancer who are losing weight (cachexia) gain or maintain weight while on chemotherapy. L-carnitine may help the body use food better and reduce muscle loss.
This study tests whether a drug already approved for other cancers can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight. The drug may help improve appetite and weight stability.
This trial tests a treatment called postbiotics (which are helpful byproducts from good bacteria) to see if they can help reduce weight loss and muscle wasting in people with advanced lung cancer. If you have this type of cancer and have been losing weight, this study might offer a way to help you feel stronger and improve your quality of life.
This study tests a new form of megestrol, a medicine that helps stimulate appetite and promote weight gain, in people with advanced non-small cell lung cancer who are starting their first chemotherapy and are at risk of malnutrition. The goal is to see if it improves nutrition and overall well-being during treatment.
Hear when a new Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.